The role of quantitative
hepatitis B surface antigen (
HBsAg) levels in patients receiving highly potent oral
antiviral therapy is controversial, and here, we determined the
HBsAg response in 121
chronic hepatitis B patients treated with
tenofovir 300 mg daily. During
tenofovir treatment,
HBsAg decline of ≥ 1.0 log from baseline was seen in 16.1%, 16.3%, 18.4%, 34.6%, 36.4% and 11.8%, 15.2%, 14.8%, 28.6%, 20% at years 1, 2, 3, 4, 5 for
HBeAg-positive and
HBeAg-negative patients, respectively. Early decline in
HBsAg levels at week 4 was predictive of subsequent significant
HBsAg level decline.
HBeAg seroconversion occurred in 29.9% of
HBeAg-positive patients. On multinomial logistic regression,
HBsAg level decline from baseline at week 4 and week 12 or any time subsequently did not correlate with
HBeAg seroconversion and HBV
DNA level decline from baseline at week 4 and week 12 (OR = 3.704; 95% CI = 1.511-9.076; P = 0.006 and OR = 1.732; 95% CI = 1.032-2.867; P = 0.037, respectively) was significantly predictive of seroconversion. A small proportion of chronic HBV-infected patients treated with
tenofovir exhibit a significant (≥ 1.0 log) decline in
HBsAg levels. Early decline in
HBsAg levels at week 4 was predictive of subsequent and significant
HBsAg level decline. The
HBsAg decline did not correlate with
HBeAg seroconversion in
HBeAg-positive patients. Reduction in HBV
DNA levels at week 4 and 12 correlated with seroconversion.